X4 Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics for rare hematology diseases. Its primary asset is mavorixafor (XOLREMDI), an orally available small-molecule selective antagonist of the CXCR4 chemokine receptor, which received FDA accelerated approval for WHIM syndrome. The company is conducting the global Phase 3 4WARD trial evaluating mavorixafor in chronic neutropenia, targeting full enrollment of 176 patients by Q3 2026 and top-line data in H2 2027. In 2025, the company raised $226.6 million in equity financing and reduced headcount by approximately 65% to focus resources on completing the 4WARD trial.
expected 2027-01-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2025-12-31 | 0001501697-26-000018 | EDGAR | 86K words |
| 2025-03-26 | 2024-12-31 | 0001628280-25-014805 | EDGAR | 86K words |
| 2024-03-21 | 2023-12-31 | 0001628280-24-012578 | EDGAR | 84K words |
| 2023-03-21 | 2022-12-31 | 0001628280-23-008745 | EDGAR | 85K words |
| 2022-03-17 | 2021-12-31 | 0001628280-22-006547 | EDGAR | 92K words |
| 2021-03-19 | 2020-12-31 | 0001628280-21-005202 | EDGAR | 93K words |
| 2020-03-12 | 2019-12-31 | 0001628280-20-003484 | EDGAR | 94K words |
| 2019-03-11 | 2018-12-31 | 0001564590-19-007097 | EDGAR | 126K words |
| 2018-03-09 | 2017-12-31 | 0001564590-18-005038 | EDGAR | 112K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-04 | 2026-09-30 | 0001501697-26-000089 | EDGAR | 18K words |
| 2026-08-06 | 2026-06-30 | 0001501697-26-000068 | EDGAR | 15K words |
| 2025-11-05 | 2025-09-30 | 0001501697-25-000043 | EDGAR | 21K words |
| 2025-08-08 | 2025-06-30 | 0001628280-25-039327 | EDGAR | 54K words |
| 2025-05-01 | 2025-03-31 | 0001628280-25-021358 | EDGAR | 50K words |
| 2024-11-13 | 2024-09-30 | 0001628280-24-047445 | EDGAR | 48K words |
| 2024-08-08 | 2024-06-30 | 0001628280-24-036127 | EDGAR | 47K words |
| 2024-05-07 | 2024-03-31 | 0001628280-24-021120 | EDGAR | 44K words |
| 2023-11-09 | 2023-09-30 | 0001628280-23-038334 | EDGAR | 52K words |
| 2023-08-10 | 2023-06-30 | 0001628280-23-028897 | EDGAR | 52K words |
| 2023-05-04 | 2023-03-31 | 0001628280-23-015763 | EDGAR | 49K words |
| 2022-11-03 | 2022-09-30 | 0001628280-22-028201 | EDGAR | 53K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-10-29 | 0001501697-26-000084 | EDGAR | 3K words |
| 2026-10-08 | 0001501697-26-000081 | EDGAR | 1K words |
| 2026-09-09 | 0001501697-26-000076 | EDGAR | 1K words |
| 2026-09-08 | 0001501697-26-000072 | EDGAR | 1K words |
| 2025-11-05 | 0001501697-25-000041 | EDGAR | 2K words |
| 2025-10-27 | 0001501697-25-000032 | EDGAR | 24K words |
| 2025-09-17 | 0001501697-25-000021 | EDGAR | 1K words |
| 2025-08-25 | 0001501697-25-000008 | EDGAR | 1K words |
| 2025-08-13 | 0001501697-25-000006 | EDGAR | 19K words |
| 2025-08-12 | 0001628280-25-039770 | EDGAR | 2K words |
219 total filings indexed. 188 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001501697 |
| Ticker | XFOR |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.x4pharma.com |
| Listed | 2017-11-16 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/XFOR (~200 tokens, structured JSON with cryptographic provenance)